Vir Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Vir Biotechnology, Inc. (VIR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.40% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-05
- Vir Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.40%, a 4.76% increase year-over-year.
- Vir Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.90%, a 13.33% decline year-over-year.
- Vir Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.20%, a 8.70% decline year-over-year.
- Vir Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.50%, a 4.65% increase year-over-year.
- Vir Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.50%, a 2.17% decline from fiscal 2024.
- Vir Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.60%, a 6.12% decline from fiscal 2023.
- Vir Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.90%, a 13.95% increase from fiscal 2022.
- Vir Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.30%, a 230.77% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.40% 10-Q · filed 2026-08-05 | 4.40% 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 4.50% 10-K · filed 2026-02-23 | |||
| 2025-06-30 | 4.20% 10-Q · filed 2026-08-05 | 4.50% 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 4.60% 10-K · filed 2026-02-23 | |||
| 2024-09-30 | 4.10% 10-Q · filed 2024-11-04 | 4.60% 10-Q · filed 2024-11-04 | ||
| 2024-06-30 | 4.60% 10-Q · filed 2024-08-01 | 4.60% 10-Q · filed 2024-08-01 | ||
| 2024-03-31 | 4.30% 10-Q · filed 2024-05-03 | |||
| 2023-12-31 | 4.90% 10-K · filed 2026-02-23 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2024-11-04 | 4.40% 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | 3.90% 10-Q · filed 2024-08-01 | 4.10% 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | 4.10% 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | 4.30% 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 3.60% 10-Q · filed 2023-11-03 | 3.60% 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | 3.30% 10-Q · filed 2023-08-04 | 3.30% 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | 2.20% 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 1.30% 10-K · filed 2024-02-26 | |||
| 2021-09-30 | 1.00% 10-Q · filed 2022-11-03 | 1.20% 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-09 | 1.20% 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 1.20% 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 1.20% 10-K · filed 2023-02-28 | |||
| 2020-09-30 | 0.40% 10-Q · filed 2021-11-04 | 1.20% 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | 0.50% 10-Q · filed 2021-08-05 | 1.20% 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | 1.20% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 2.50% 10-K · filed 2022-02-28 | |||
| 2019-09-30 | 2.50% 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | 3.00% 10-K · filed 2021-02-25 | |||
| 2018-09-30 | 2.90% 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | 2.20% 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |